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CREST is a prospective, randomized, multicenter clinical
trial of CEA versus CAS for prevention of stroke in
patients with symptomatic stenosis greater than or equal
to 50% [1]. The study includes a lead-in phase to ensure
that research participant treatment is the same for all sites,
and to collect data on the outcome of procedures per-
formed by interventionists who have previously been
trained and evaluated in the use of the study stent. These
data will be reviewed by the Interventional Management
Committee that is responsible for approving and creden-
tialing interventionists to perform the stent procedure in
CREST. CREST is supported by US NINDS-NIH through
the investigator-originated (R01) grant mechanism, and is
in the process of being converted into a co-operative
agreement (U01). The organizational structure for CREST
is shown in Fig. 1.
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Abstract
The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is a prospective,
randomized, multicenter clinical trial of carotid endarterectomy (CEA) versus carotid artery stenting
(CAS) as prevention for stroke in patients with symptomatic stenosis greater than or equal to 50%.
CREST is sponsored by the US National Institute of Neurological Disorders and Stroke (NINDS) of the
US National Institutes of Health (NIH), with additional support by a device manufacturer, and will
provide data to the US Food and Drug Administration (FDA) for evaluation of a stent device. Because
of budget constraints for CREST, Health Care Financing Administration (HCFA) reimbursement for
hospital costs incurred by CREST patients will be essential. The involvement of academic scientists,
industry, and three separate government agencies (NIH, FDA, HCFA) has presented many challenges
in conducting the trial. A review of the pathways followed to meet these challenges may be helpful to
others seeking to facilitate sharing of the costs and burdens of conducting innovative clinical research.







Several other federal agencies have played major roles in
the development of the study. The US FDA is interested in
CAS because of its increased use, and because industry
sponsors have wanted to broaden the indications for CAS
in the management of extracranial carotid occlusive
disease. The CREST investigators have worked closely
with the FDA to meet the FDA’s regulatory responsibilities
and CREST’s need for data that would underpin requests
for regulatory approval of CAS devices.
During the late 1990s, the use of carotid angioplasty (arte-
rial dilatation without insertion of a stent) expanded
rapidly, without clinical trial data to support efficacy. In
response, the HCFA issued a national noncoverage policy
against reimbursement to hospitals for expenses incurred
by use of carotid angioplasty in Medicare patients.
(Medicare is the US federal government insurance
program for people aged 65 years or older, certain young
people with disabilities, and people with end-stage renal
disease.) This moratorium was issued because of the lack
of scientific and clinical evidence regarding the effective-
ness of carotid angioplasty. Subsequently, this moratorium
against carotid angioplasty was extended to cover carotid
stenting as well. Because third party payers use HCFA
payment as part of their guidelines for reimbursement, this
decision resulted in many payers also declining to reim-
burse expenses incurred with carotid angioplasty, with or
without stenting.
Submission of CREST proposals to the US
National Institutes of Health
In 1996, a group of clinical scientists representing a
number of disciplines (neurology, cardiology, interven-
tional radiology, neuroradiology, vascular surgery, neuro-
surgery, and biostatistics /epidemiology) began to develop
a proposal for comparing the relative efficacies of CEA
and CAS (Table 1). This original submission was a ‘proof
of principle’ trial, in which stents from a variety of manufac-
turers would be allowed at the discretion of the interven-
tionist. The aim of the study was to contrast ‘best’ CEA
versus ‘best’ CAS. In January 1997, as part of the prepa-
ration for this original grant application, the CREST Execu-
tive Committee had several meetings with the HCFA that
resulted in written assurance that a funded NIH grant,
coupled with FDA approval, would ensure coverage for
the parts of the CREST protocol that dealt with ‘carotid
angioplasty with stents and related services’. As part of
the initial application, representatives of the CREST inves-
tigative team also had a series of meetings with the FDA
to review a draft protocol and to discuss procedures for
Figure 1
CREST organizational structure. ACS, Advanced Cardiovascular Systems. Inc; ECG, electrocardiography.
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the interpretation of results in order to provide ‘proof of
principle’ for CAS in general, and for the broadening of
indications for the specific devices produced by manufac-
turers. The resulting letter of support from the FDA was
included in the initial application.
The proposal was peer reviewed for the NINDS in Sep-
tember 1997. The reviewers recommended restricting the
study to a single stent device, clarifying the use of ultra-
sound and angiography in determining stenosis eligibility,
further specifying the training and certification of interven-
tionists, and modifying plans for interim analyses. The pro-
posal was then revised and resubmitted to the NIH in May
1998. While awaiting the second NIH review, the CREST
Principal Investigator began negotiations with several
manufacturers that could provide carotid stents for the
trial. By the time of the second peer review, in July 1998,
no industry partner had been selected.
After the CREST grant was approved by the
US National Institute of Neurological
Disorders and Stroke
In early 1999, after approval but before the award of the
CREST grant, negotiations continued with the device
companies. The Guidant Corporation, the manufacturer of
ACCULINK® Carotid Stent System, agreed to work with
the CREST investigators to modify the peer-reviewed pro-
tocol so that the needs of the NINDS, the FDA, and the
Guidant Corporation (Indianapolis, IN, USA) could all be
addressed. As part of the agreement, the Guidant Corpo-
ration would provide assistance with training of the investi-
gators and with additional site monitoring in order to
comply with FDA requirements.
The industry sponsor for the trial holds the FDA investiga-
tional device exemption (IDE). An IDE is an exemption that
allows an investigational device to be used in a clinical
study to collect safety and effectiveness data without
complying with all other FDA requirements that would
apply to devices in commercial distribution. It is the policy
of the NIH, when it funds all or part of a clinical study con-
ducted under an IDE, that the ‘awardee institution’ and the
NIH be kept informed of any significant communications
with the FDA about the study. [2] This required line of
communication is complicated by the statute that the FDA
should communicate only with the sponsor of the IDE, in
this case the Guidant Corporation, rather than the Princi-
pal Investigator. Because the Guidant Corporation was to
hold the IDE, it was responsible for submission of the pro-
tocol to the FDA. Negotiations between academic and
industry partners in CREST had to carefully define access
to data in order to meet the needs of the NINDS, industry,
and the FDA, while maintaining appropriate masking and
integrity of the study.
Dual goals of the CREST protocol
For the FDA, and to meet the needs of the CREST indus-
trial partner, the data from CREST will also be used to
address an aim other than the one originally proposed by
the CREST investigators to the NINDS. The CREST inves-
tigators and the NINDS are interested in establishing dif-
ferences in the long-term efficacy of CEA versus that of
CAS, whereas the FDA and industry are interested in
establishing whether CAS is ‘as effective or more effec-
tive’ than CEA in preventing stroke at 1 year of follow up.
These different needs for the data give rise to two
‘primary’ analyses for CREST, with substantial differences
(Table 1). As part of the protocol approved by NINDS peer
review, the CREST investigators’ null hypothesis of ‘no dif-
ference between two treatments in the average hazard
over 4 years of follow-up’ is contrasted with an alternative
hypothesis that ‘one treatment is better (a two-tailed test)’.
These hypotheses will be addressed by contrasting the
average time to event using traditional statistical methods
for survival analysis.
Through a series of meetings with the FDA, it became
apparent that an ‘equivalency’ analysis would be used by
the FDA for decisions regarding the device, including
revisions to the instructions for the use of the device that
would broaden the categories of patients in which use of
the stent would be appropriate. In this ‘equivalence’
approach, the null hypothesis is that ‘CAS has an event
rate marginally higher (by a difference of 2.6%) than
CEA at the 1-year point in the follow-up’. The alternative
Table 1
Timeline of major CREST-related events
Date Event
March 1996 Grant application development
Jan 1997 HCFA letter of support for CREST group
Feb 1997 1st NIH grant application submitted 
Sept 1997 1st NIH grant application review 
May 1998 Revised grant application submitted to NIH
May 1998 Negotiations with device companies
July 1998 2nd NIH grant application review
Jan 1999 Grant awarded
May 2000 HCFA withdraws support
June 2000 Executive order for HCFA participation in clinical 
trials
August 2000 HCFA support reinstated
December 2000 First patient enrolled
March 2001 HCFA decision for modification of noncoverage 
policy
July 2001 Effective date for HCFA reimbursement policy
‘superiority’ hypothesis would be that ‘the CAS event rate
is as low (within a difference of 2.6%) or lower than CEA
(a one-tailed test)’ (Table 2). These hypotheses will be
addressed by comparing Kaplan–Meier estimates of
stroke-free survival at a fixed point during the patient
follow up (1 year) after the procedure.
Having two groups deciding the value of CEA versus that
of CAS using different hypotheses opens the possibility
that ‘discordant’ study results may occur. For example, the
CREST investigators’ superiority analysis could conclude
that CEA has a lower event rate than CAS, whereas the
FDA analysis could conclude that CAS is as good or
better than CEA. Such a result would place the scientific
community at odds with a possible FDA approval to
broaden the label of an already approved device. In con-
sultation with the CREST Data and Safety Monitoring
Board (DSMB), the CREST investigators considered the
likelihood of discordant findings using a simulation
approach that considered a wide range of study out-
comes. These results suggest that there is less than a
1/1000 chance of a discordant finding [3].
Logistical Issues
As well as study design challenges introduced by the dual
use of the data, many logistical issues needed to be con-
sidered. For CREST to move forward, the protocol had to
be approved by both NINDS and the FDA. The NINDS
would not award the grant until it was clear that a satisfac-
tory agreement could be reached with a stent manufac-
turer. The final protocol (and subsequent modifications by
the CREST investigators) had to be approved by the
DSMB appointed by NINDS [4,5]. There was no mecha-
nism, however, for the DSMB and the FDA to meet
together, because the DSMB was only advisory to the
NINDS. The NINDS program directors for CREST
attended all of the FDA and the Guidant Corporation
meetings to which they were invited. When subsequent
protocol changes were ‘suggested’ by the FDA, however,
the details of these changes had to first be negotiated
with the CREST investigators, then with the Guidant Cor-
poration, and then the finalized changes submitted for
review by the NINDS and the DSMB. Likewise, when sub-
sequent protocol changes were ‘suggested’ by the
DSMB, the details of these changes had to be negotiated,
and then submitted to the FDA for their review. The FDA is
required by regulation to complete this review within 30-
days of receipt.
Despite efforts to facilitate the communication with elec-
tronic mail, the process was made cumbersome by the
formal channels of communication from CREST investiga-
tors to the NINDS, who then communicated with the
DSMB, and from the CREST investigators to the Guidant
Corporation, who then communicated with the FDA. The
protocol development process was, however, facilitated by
joint FDA, NINDS, Guidant Corporation, and CREST inves-
tigator meetings. Clearly, in order to co-ordinate research
among the NIH, academic investigators, manufacturers,
and the FDA, communication is greatly complicated and
research may be delayed when the FDA and NINDS peer
reviewers do not agree on a single study design.
An additional conflict of responsibilities arose because
the FDA required Guidant Corporation (as the holder of
the IDE) to be the primary depository of regulatory docu-
ments, such as Institutional Review Board approval.
However, NINDS requires the office of the Principal
Investigator to be the primary depository of these docu-
ments. Therefore, obtaining required documentation is a
complex organizational feat that requires clear lines of
communication and record keeping in order to minimize
confusion from staff at the local clinical sites. For
example, conflict of interest statements, approved
informed consent documents, and Institutional Review
Board approval documentation are independently
required by the awardee institution for NINDS, and by the
Guidant Corporation for the FDA. This duplication
creates additional burden in the conduct of the study.
Obtaining reimbursement from the Health
Care Financing Administration
As noted above, in January 1997, contingent on NIH
funding and FDA approval, the HCFA committed in writing
to support reimbursement for the stents placed as part of








Differences between the CREST and the Guidant Corporation/FDA analysis
Aspect of the trial Superiority (CREST) Equivalence (Guidant Corporation/FDA analysis)
Hypothesis format Traditional Equivalency
Primary events Stroke, myocardial infarction, or death in 30 days; Stroke, myocardial infarction, or death in 30 days; 
ipsilateral stroke thereafter ipsilateral stroke thereafter
Follow-up Variable follow up (1–4 years) 1-year follow up
Statistical comparison Differences in hazard of event Event rate at 1 year
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pal Investigator received verbal notification that the HCFA
‘would be unwilling to grant [CREST] an exception to the
national noncoverage policy for reimbursement for carotid
angioplasty with stenting’. Changes in HCFA personnel
and policies had occurred in the interim, and contributed
to this reversal. 
The decision of the HCFA to deny reimbursment resulted
in a near shutdown of CREST start-up activities. Although
24 clinical centers had already participated in a CREST
investigators’ meeting and co-ordinator training session,
further initiation activities were placed on hold because of
the uncertainty regarding the future of the trial due to the
lack of resources to pay for the hospitalization and stan-
dard care of patients randomized in CREST.
Over several months, NINDS, the Guidant Corporation, and
the FDA met with the HCFA in an attempt to resolve the
problem. On June 7, 2000, the President of the United
States issued an Executive Order to instruct the HCFA to
provide support for patients participating in clinical trials [6].
On August 3, 2000, at an additional meeting with the
HCFA, the CREST investigators were informed that, as a
NINDS-approved clinical trial, there would be reimburse-
ment for the procedures performed in CREST. On March
19, 2001, the HCFA issued a final decision modifying the
noncoverage policy on carotid stenting [7]. The decision
was made to cover ‘percutaneous transluminal angioplasty
of the carotid artery concurrent with stent placement in clini-
cal trials that receive a Category B IDE designation from the
FDA’ [7]. Category B devices are nonexperimental/
investigational devices.
Conclusion
Although dealing with different government agencies,
industry, and an academic institution (with associated sub-
contracting institutions) created substantial hurdles, com-
munication was a key component for a successful and
viable grant application, and remains the key to the suc-
cessful conduct and completion of CREST. Underlying
this is an acknowledgment of the importance of a trial that
examines carotid stenting. This is shared not only by the
CREST investigators and NINDS, but also by the repre-
sentatives of industry, the FDA, and the HCFA. Through
this commitment by all involved, the substantial hurdles
have been overcome and the study is now underway.
As of mid-June 2001, 47 centers have been selected to
participate in CREST. Eight centers are approved to enroll
participants in the lead-in phase, one center is approved
to enroll participants in the randomization phase, and the
remaining centers are in various stages of completing the
regulatory and certification requirements. CREST is in an
optimal position to demonstrate whether academic institu-
tions, government agencies, and industry can work
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